The generic name for Tofacitinib is tofacitinib [1].
When was Tofacitinib first approved?
Tofacitinib was first approved in November 2012 [1].
What conditions is Tofacitinib used to treat?
Tofacitinib is approved for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate [1]. It is also indicated for active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate, and for moderately to severely active ulcerative colitis in adults who have had an inadequate response or intolerance to TNF inhibitors [1].
What is the mechanism of action for Tofacitinib?
Tofacitinib is a Janus kinase (JAK) inhibitor [1]. It works by blocking the activity of JAK enzymes, which are involved in the signaling pathways of various cytokines and growth factors that play a role in inflammation and immune response [1].
How does Tofacitinib compare to other treatments for rheumatoid arthritis?
Tofacitinib offers an alternative for patients with rheumatoid arthritis who have not responded adequately to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) [1]. Its efficacy in treating active psoriatic arthritis and ulcerative colitis also provides options for patients who have failed other therapies, such as TNF inhibitors [1].
When does Tofacitinib's patent protection end?
Patent information for Tofacitinib, including expiry dates, can be found on DrugPatentWatch.com [2]. Companies often seek to extend patent protection through various legal and regulatory strategies.
Are there generic versions of Tofacitinib available?
The availability of generic versions of Tofacitinib depends on patent expiry and regulatory approvals in different regions [2]. Information on generic availability can be accessed through resources like DrugPatentWatch.com [2].
What are the potential side effects of Tofacitinib?
Common side effects associated with Tofacitinib include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis [1]. More serious risks include serious infections, malignancy, thrombosis, and laboratory abnormalities [1]. Patients should discuss potential risks and benefits with their healthcare provider.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/